Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease
about
Rapamycin and rapalogs for tuberous sclerosis complexRapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysisTargeted therapeutic strategies for the management of renal cell carcinomaOptimal treatment of tuberous sclerosis complex associated renal angiomyolipomata: a systematic reviewIs mTOR Inhibitor Good Enough for Treatment All Tumors in TSC Patients?Management of lymphangioleiomyomatosisPrevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM)Tuberous sclerosis complex surveillance and management: recommendations of the 2012 International Tuberous Sclerosis Complex Consensus Conference.Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trialThe neural crest lineage as a driver of disease heterogeneity in Tuberous Sclerosis Complex and Lymphangioleiomyomatosis.Similar trends in serum VEGF-D levels and kidney angiomyolipoma responses with longer duration sirolimus treatment in adults with tuberous sclerosis.Retrospective review of combined sirolimus and simvastatin therapy in lymphangioleiomyomatosisSustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis.Fibrous papule of the face, similar to tuberous sclerosis complex-associated angiofibroma, shows activation of the mammalian target of rapamycin pathway: evidence for a novel therapeutic strategy?Insight into response to mTOR inhibition when PKD1 and TSC2 are mutatedTuberous Sclerosis: A New Frontier in Targeted Treatment of AutismImprovement of tuberous sclerosis complex (TSC) skin tumors during long-term treatment with oral sirolimusDifferentiating the mTOR inhibitors everolimus and sirolimus in the treatment of tuberous sclerosis complex.Cutaneous manifestations of tuberous sclerosis complex and the paediatrician's role.Lymphangioleiomyomatosis - a wolf in sheep's clothing.Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial.Lymphangioleiomyomatosis: current and future.Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors.Extrarenal perivascular epithelioid cell tumors (PEComas) respond to mTOR inhibition: clinical and molecular correlates.mTOR inhibitors block Kaposi sarcoma growth by inhibiting essential autocrine growth factors and tumor angiogenesis.Pharmacokinetics and pharmacodynamics of everolimus in patients with renal angiomyolipoma and tuberous sclerosis complex or lymphangioleiomyomatosis.Targeted treatment trials for tuberous sclerosis and autism: no longer a dream.A phase I study of the combination of temsirolimus with irinotecan for metastatic sarcomaEverolimus in the treatment of subependymal giant cell astrocytomas, angiomyolipomas, and pulmonary and skin lesions associated with tuberous sclerosis complex.Mammalian target of rapamycin (mTOR) pathways in neurological diseases.Tuberous sclerosis complex, mTOR, and the kidney: report of an NIDDK-sponsored workshop.Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.mTOR inhibitors in the pharmacologic management of tuberous sclerosis complex and their potential role in other rare neurodevelopmental disorders.Hepatic manifestations of tuberous sclerosis complex: a genotypic and phenotypic analysis.Histology-specific therapy for advanced soft tissue sarcoma and benign connective tissue tumors.Are developmental dysplastic lesions epileptogenic?Interstitial lung diseases-can pathologists arrive at an etiology-based diagnosis? A critical update.Functional diversity and pharmacological profiles of the FKBPs and their complexes with small natural ligands.Evolving neurobiology of tuberous sclerosis complex.Targeting the PI3K/AKT/mTOR pathway: biomarkers of success and tribulation.
P2860
Q26471128-FB6CBAA6-090A-44B5-9526-71CB7172D8CAQ26799757-01C4E30A-09FB-47C5-BEE5-BEEA694B90D2Q27013846-592D1FA8-E355-468F-8592-8C03E906D6C6Q28071646-F66E028F-4E70-40DB-A59D-330779333DE6Q28075954-4B78A08A-D18C-4386-9FAC-4E9808D2C348Q28084725-4D0E25C6-2B6D-41F7-993E-DB445D3749A0Q30540707-45B31CD4-1B76-47E9-A8A7-30437B3D88C1Q33757948-F973FA3C-AD0D-4F85-929C-F7DA50B75D12Q34380247-1880D536-063C-45D5-8C16-88C0D49F8F1CQ34569989-3DF7BABA-505D-40B0-9FD0-093468814DD7Q34598409-AB33C3EA-5558-402A-94DE-C12F243FCB87Q34840298-3600B8CE-3319-44FA-9D03-CC2923BE05B8Q35044713-D2B01BD8-7E73-4B11-8696-A2E2C469B3EBQ35099876-AD06D059-7A0B-449D-BCD1-4E49FA3034B9Q35664471-683FAAFD-8D11-49DD-A980-A3BBAC73320DQ35811772-913811C9-8A15-4EDF-A02D-AB2CF9BBAB05Q36173629-7D2E70A5-F43D-4887-A3F6-86242B6180E9Q36250754-3CD7F936-0A41-4E1E-9677-7AD6CAC4781EQ36326114-B68FF5D7-EA45-4BF4-BBCF-CFB5A9823F89Q36357766-8BA6B3F7-951C-4FBA-B0AC-FE8BFC97DCAFQ36459311-FF7B7D6F-1E58-4BB7-B96E-0864EA167C49Q36542254-839FD38E-6391-4752-A2D4-ECA04D4C1526Q36549186-DEF6D7D7-B752-41A4-A793-39FFD47D3E80Q36572374-8A79DA37-B0F3-4C6D-9917-FABC151F97A3Q36745445-4F06E7C3-A4C2-44FB-9F47-6A8F24EC5C13Q36806587-9E757507-090F-491D-8902-66EE40BC72CAQ37025554-3FBD83E1-E935-4FAB-9701-17F106B5426DQ37061813-01CF2ECF-F502-4EC7-98DA-1FA15D19CC52Q37232131-032B61B3-F239-4D22-A7BC-B0108C7CAB8CQ37432305-EA5C3899-EE0A-4A1A-B78C-4A4F9A4038BFQ37575580-3E5D387C-2A80-42B7-AA80-BB000702E4C5Q37596461-31A9BDA6-82F7-44A9-B518-36EB05038447Q37697798-656BAF1B-47D4-4D3B-8876-B4CFBA782BE8Q37976482-976E3862-6AFA-4700-855C-466C8195FED8Q38011606-3A4A77BD-7850-4C0B-A13E-3C60F1404BA9Q38011832-69E6540A-5B75-4B2B-A4FC-5BAF5331E0BEQ38065960-4906BFD0-3065-4EA9-8D79-D9626283A8C9Q38065993-A76E7B87-EE8D-41DE-9624-6AAF4CEE58DDQ38079547-47960613-273E-49F6-9D34-49D78EFC0DC7Q38110087-6ED2359B-25E7-4A27-B493-C71A1661CADD
P2860
Multicenter phase 2 trial of sirolimus for tuberous sclerosis: kidney angiomyolipomas and other tumors regress and VEGF- D levels decrease
description
2011 nî lūn-bûn
@nan
2011 թուականին հրատարակուած գիտական յօդուած
@hyw
2011 թվականին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Multicenter phase 2 trial of s ...... ss and VEGF- D levels decrease
@ast
Multicenter phase 2 trial of s ...... ss and VEGF- D levels decrease
@en
Multicenter phase 2 trial of s ...... ss and VEGF- D levels decrease
@nl
type
label
Multicenter phase 2 trial of s ...... ss and VEGF- D levels decrease
@ast
Multicenter phase 2 trial of s ...... ss and VEGF- D levels decrease
@en
Multicenter phase 2 trial of s ...... ss and VEGF- D levels decrease
@nl
prefLabel
Multicenter phase 2 trial of s ...... ss and VEGF- D levels decrease
@ast
Multicenter phase 2 trial of s ...... ss and VEGF- D levels decrease
@en
Multicenter phase 2 trial of s ...... ss and VEGF- D levels decrease
@nl
P2093
P2860
P3181
P1433
P1476
Multicenter phase 2 trial of s ...... ss and VEGF- D levels decrease
@en
P2093
Arthur Sagalowsky
Chelsey Woodrum
Daniel Miles
Darcy Krueger
David Neal Franz
Drew Cutler
Elizabeth A Thiele
Fiona Fennessy
Francis J DiMario
Jan Paolini
P2860
P304
P3181
P356
10.1371/JOURNAL.PONE.0023379
P407
P577
2011-01-01T00:00:00Z